Most people starting HIV treatment for the first time (treatment naïve) should take one of the following: Biktarvy; Triumeq; Tivicay plus Descovy or Truvada; or Isentress HD or Isentress, plus Descovy or Truvada.
Rating of Recommendations
Rating of Evidence
I: Data from randomized controlled trials
II: Data from well-designed non-randomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies
III: Expert opinion
ART: antiretroviral therapy
CD4: CD4 T lymphocyte, “T cell”
FDA: Food and Drug Administration
HLA: human leukocyte antigen
INSTI: integrase strand transfer inhibitor
NNRTI: non-nucleoside reverse transcriptase inhibitor
NRTI: nucleoside reverse transcriptase inhibitor
PI: protease inhibitor
STR: single-tablet regimen
TAF: tenofovir alafenamide
TDF: tenofovir disoproxil fumarate
NOTE: The following are available as co-formulated drugs
(Not a complete list)
EFV 600 mg/3TC/TDF
Cimduo or Temixys
1 Lamivudine (3TC) may substitute for emtricitabine (FTC) or vice versa.
- Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are two forms of tenofovir that are approved by the Food and Drug Administration. TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between the two.
- raltegravir (RAL) can be given as RAL 400 mg twice daily or RAL 1200 mg (two 600 mg tablets) once daily.